Calidi Cuts Costs, Raises $1.2 Million
Calidi Biotherapeutics said it advanced its CLD-401 cancer-treatment candidate and presented new preclinical findings at the 2026 ESMO Congress. In mouse studies, CLD-401 eradicated tumors in 80% of one breast-cancer model and showed activity in a bladder-cancer model when administered intravenously or directly into tumors; the company also reported progress on its in situ T-cell engager platform. Calidi reported a 39% year-over-year reduction in third-quarter general and administrative expenses, raised $1.2 million through an offering, and said a restructuring plan is intended to save $3 million annually and extend its cash runway. A separate earnings report put the quarter’s loss at $1.47 per share and said shares fell to $0.62 on Friday.




